Company: VMCWF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001827
Chunk: 10

Company: Valuence Merger Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 10
---
. Cho is focused on developing
growth strategies as well as providing strategic planning and management of the operations and expansion of CG Pharmaceuticals. Additionally,
Dr. Cho supports U.S. clinical trial management. Previously, Dr. Cho worked as a life sciences consultant at L.E.K. Consulting, working
with clients in biopharmaceuticals, contract services, medical devices, healthcare services, HCIT, digital health, and AI. Some of his
specific experiences include working on large-scale M&A transactions of leading biopharmaceuticals or healthcare service companies,
supporting target identification for acquisition, implementing pipeline development strategies, and optimizing governance structures
of fast-growing biotech companies. He also brings strong experience in the Asian markets through his professional network focused around
supporting emerging technologies and startups. Dr. Cho received his B.S. in bioengineering at U.C. Berkeley and Ph.D. from the NYU School
of Medicine in biomedical imaging; he also completed his post-doctorate at Memorial Sloan Kettering focusing on breast cancer imaging.
Dr. Cho is also the author of over 10 publications in journals and several conference abstracts during his time as a researcher.

With
respect to the above, past experience or performance of our management team and the businesses with which they have been associated is
not a guarantee of either (i) our ability to successfully identify and consummate a Business Combination or (ii) success with respect
to any Business Combination that we may consummate. You should not rely on the historical record of our management team or the businesses
with which they have been associated as indicative of our future performance. No member of our management team has any experience in
operating special purpose acquisition companies.

Business
Strategy

Our
business strategy is to identify, acquire, and maximize the value of a target operating in Asia, excluding China, Hong Kong and Macau,
with a focus on either life sciences or sustainable technology - a target who can benefit from (i) our geographic understanding of both
Asia and North America, (ii) the financial and operational experience of our management team and the Board of Directors, (iii) additional
capital to fund its strategic objectives, and (iv) access to public securities markets.

Our
target selection process is expected to leverage our management team’s network of potential transaction sources, ranging from owners
and directors of private and public companies, private equity funds, investment bankers, lenders, attorneys, accountants, and other trusted
advisors across various sectors. Over the course of